Global Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), API Type (CMO, In-house), Drug Class, Application, End User - Forecast 2023-2030- Product Image

Sale

Global Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), API Type (CMO, In-house), Drug Class, Application, End User - Forecast 2023-2030

Report
186 Pages
March 2024
Region: Global
360iResearch™
ID: 4968565

UP TO €850EUR$875USD£733GBP OFF until Dec 31^st 2024

The Peptide Therapeutics Market size was estimated at USD 30.10 billion in 2022, USD 33.40 billion in 2023, and is expected to grow at a CAGR of 11.03% to reach USD 69.56 billion by 2030.

Peptide therapeutics refers to the use of short chains of amino acids for the treatment or prevention of various diseases and medical conditions. These biologically active molecules possess unique properties that make them an efficient option in drug development and pharmaceutical research. The surging prevalence of chronic diseases, including cancer and diabetes, is raising the need for effective treatment options and an improved understanding of protein-protein interactions leading to targeted therapies. Growing investment in research & development activities and a robust clinical pipeline with therapeutic candidates are resulting in the development of novel peptide therapeutics. However, the inherent instability of peptides and the high cost of manufacturing peptides may adversely impact the development of peptide therapeutics. Moreover, recent developments in drug delivery systems are expected to expand the potential applications for peptides.

Regional Insights

The peptide therapeutics market is evolving in the Americas owing to the presence of well-established pharmaceutical industries, an increase in research activities, and a growing number of approved peptide drugs. Patent activity in this region is notable, with several prominent pharmaceutical companies headquartered in the area. In recent years, investments in innovative peptide formulations have also increased, indicating a strong market potential for new therapeutic approaches. The peptide therapeutics market is developing in the EMEA region due to the regulatory framework supporting innovation within biotechnology and funding research projects related to peptide therapeutics. The rising prevalence of chronic disease, improving healthcare infrastructure, and growing awareness regarding peptide therapeutics are encouraging the growth of the peptide therapeutics market in the APAC region. Besides, ongoing advancements and the development of more efficient, scalable, and cost-effective synthetic strategies for producing peptides are anticipated to encourage the development and adoption of peptide therapeutics globally.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Peptide Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Peptide Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AmbioPharm Inc., Amgen Inc., Arcturus Therapeutics Holdings Inc., AstraZeneca PLC, Bachem AG, Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Dynavax Technologies Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Ipsen, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Piramal Group (Piramal Pharma Solution), PolyPeptide Group, Relief Therapeutics Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Hybrid Phase
- Liquid Phase
- Solid Phase
API Type
- CMO
- In-house
Drug Class
- Calcitonins
- Glucagon & Analogs
- Insulins
- Luteinizing Hormone-Releasing Hormone
- Somatostatins
- Vasopressin
Application
- Anti-infective
- Cancer
- Cardio Vascular Disease Respiratory
- Central Nervous System
- Dermatology
- Gastrointestinal
- Metabolic
- Renal
End User
- Hospitals
- Pharmaceutical Industries
- Research Laboratories

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Peptide Therapeutics Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Peptide Therapeutics Market?
What are the technology trends and regulatory frameworks in the Peptide Therapeutics Market?
What is the market share of the leading vendors in the Peptide Therapeutics Market?
Which modes and strategic moves are suitable for entering the Peptide Therapeutics Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Peptide Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer, cardiovascular disorders (CVDs) and metabolic disorder
5.1.1.2. Technology advancement and R & D investment in new peptides
5.1.2. Restraints
5.1.2.1. Poor chemical and physical stability and a short circulating plasma half-life of naturally occurring peptides
5.1.3. Opportunities
5.1.3.1. Presence of strong product pipeline portfolio
5.1.3.2. Adoption of new platforms that develop next-generation protein or peptide therapeutics
5.1.4. Challenges
5.1.4.1. Presence of stringent safety regulations
5.2. Market Segmentation Analysis
5.2.1. Technology: Utilization of solid phase approach for synthesis of complex peptides
5.2.2. API Type: Proliferating production of peptide therapeutics through Contract Manufacturing Organizations (CMOs)
5.2.3. Application: Extensive use of peptide therapeutics for cancer treatment
5.2.4. End User: Significant adoption of peptide therapeutics by hospitals
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization

6. Peptide Therapeutics Market, by Technology

6.1. Introduction
6.2. Hybrid Phase
6.3. Liquid Phase
6.4. Solid Phase

7. Peptide Therapeutics Market, by API Type

7.1. Introduction
7.2. CMO
7.3. In-house

8. Peptide Therapeutics Market, by Drug Class

8.1. Introduction
8.2. Calcitonins
8.3. Glucagon & Analogs
8.4. Insulins
8.5. Luteinizing Hormone-Releasing Hormone
8.6. Somatostatins
8.7. Vasopressin

9. Peptide Therapeutics Market, by Application

9.1. Introduction
9.2. Anti-infective
9.3. Cancer
9.4. Cardio Vascular Disease Respiratory
9.5. Central Nervous System
9.6. Dermatology
9.7. Gastrointestinal
9.8. Metabolic
9.9. Renal

10. Peptide Therapeutics Market, by End User

10.1. Introduction
10.2. Hospitals
10.3. Pharmaceutical Industries
10.4. Research Laboratories

11. Americas Peptide Therapeutics Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Peptide Therapeutics Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Peptide Therapeutics Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Agreement, Collaboration, & Partnership
14.3.1.1. MSD Extends Peptide Collaboration with IRBM
14.3.2. New Product Launch & Enhancement
14.3.2.1. Fujitsu launches “Biodrug Design Accelerator” platform to accelerate peptide drug discovery research
14.3.2.2. SynCrest Launches CRDMO Service for Peptide-based Therapeutics

15. Competitive Portfolio

15.1. Key Company Profiles
15.1.1. AmbioPharm Inc.
15.1.2. Amgen Inc.
15.1.3. Arcturus Therapeutics Holdings Inc.
15.1.4. AstraZeneca PLC
15.1.5. Bachem AG
15.1.6. Bristol Myers Squibb Company
15.1.7. Cidara Therapeutics, Inc.
15.1.8. Corden Pharma International GmbH
15.1.9. Dynavax Technologies Corporation
15.1.10. Eli Lilly and Company
15.1.11. F. Hoffmann-La Roche Ltd
15.1.12. GlaxoSmithKline PLC
15.1.13. Ipsen
15.1.14. Merck & Co., Inc.
15.1.15. Novartis AG
15.1.16. Novo Nordisk A/S
15.1.17. Otsuka Pharmaceutical Co., Ltd.
15.1.18. Pfizer Inc.
15.1.19. Piramal Group (Piramal Pharma Solution)
15.1.20. PolyPeptide Group
15.1.21. Relief Therapeutics Holding AG
15.1.22. Sanofi S.A.
15.1.23. Takeda Pharmaceutical Company Limited
15.1.24. Teva Pharmaceutical Industries Ltd.
15.1.25. Zealand Pharma A/S
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing

List of Figures

FIGURE 1. PEPTIDE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. PEPTIDE THERAPEUTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. PEPTIDE THERAPEUTICS MARKET DYNAMICS
FIGURE 7. PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 8. PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2022 VS 2030 (%)
FIGURE 10. PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
FIGURE 12. PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 14. PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 16. PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 20. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 26. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 6. PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 10. PEPTIDE THERAPEUTICS MARKET SIZE, BY CMO, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 13. PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. PEPTIDE THERAPEUTICS MARKET SIZE, BY GLUCAGON & ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. PEPTIDE THERAPEUTICS MARKET SIZE, BY LUTEINIZING HORMONE-RELEASING HORMONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. PEPTIDE THERAPEUTICS MARKET SIZE, BY SOMATOSTATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 20. PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. PEPTIDE THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIO VASCULAR DISEASE RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. PEPTIDE THERAPEUTICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. PEPTIDE THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. PEPTIDE THERAPEUTICS MARKET SIZE, BY RENAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. PEPTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL INDUSTRIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 49. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 50. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 77. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 81. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 82. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 91. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 92. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 122. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 138. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 143. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 147. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 148. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 153. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 158. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 168. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 182. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 183. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 188. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 193. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 212. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 213. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 228. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 242. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 243. PEPTIDE THERAPEUTICS MARKET LICENSE & PRICING

Companies Mentioned

AmbioPharm Inc.
Amgen Inc.
Arcturus Therapeutics Holdings Inc.
AstraZeneca PLC
Bachem AG
Bristol Myers Squibb Company
Cidara Therapeutics, Inc.
Corden Pharma International GmbH
Dynavax Technologies Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Ipsen
Merck & Co., Inc.
Novartis AG
Novo Nordisk A/S
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
Piramal Group (Piramal Pharma Solution)
PolyPeptide Group
Relief Therapeutics Holding AG
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Zealand Pharma A/S

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	186
Published	March 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 33.4 Billion
Forecasted Market Value ( USD ) by 2030	$ 69.56 Billion
Compound Annual Growth Rate	11.0%
Regions Covered	Global
No. of Companies Mentioned	25

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3277EUR$3,374USD£2,827GBP €3641EUR$3,749USD£3,141GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4151EUR$4,274USD£3,581GBP €4613EUR$4,749USD£3,979GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5025EUR$5,174USD£4,335GBP €5584EUR$5,749USD£4,817GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5900EUR$6,074USD£5,089GBP €6555EUR$6,749USD£5,655GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7648EUR$7,874USD£6,598GBP €8498EUR$8,749USD£7,331GBP

Regional Insights

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Peptide Therapeutics Market Size, Share & Trends Analysis Report by Application (Cancer, Metabolic Disorders), Type (Generic, Innovative), Type of Manufacturer, Route of Administration, Synthesis Technology, Region, and Segment Forecasts, 2024-2030

Peptide Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

Peptide Therapeutics Global Market Report 2024

Global Peptide Therapeutics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029